2 March 2024 in Cytotherapy
1 July 2020 in Pediatric Hematology/Oncology and Immunopathology
Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by microplatelet thrombocytopenia, eczema, frequent infections and an increased risk of autoimmune disorders and malignant neoplasms. Mutation detection in WAS gene is the gold standard for diagnosis of this disorder. This gene encodes a WASP protein, which works as regulator of cell cytoskeleton and is involved in the transmission of many intracellular signals. Nowadays there is no rapid and reliable method that allows to confirm WAS in a short period of time. Early detection of WAS in patients enables initiation of a donor search and preparation for the HSCT procedure. It also helps to avoid the development of severe and life-threatening conditions during waiting for genetic confirmation of the diagnosis by using pathogenetic therapy. Currently flow cytometry is one of the leading laboratory methods that permits to get the information about the expression of a protein in several hours. The study below describes rapid and reliable based on flow cytometry assay for WAS diagnosis. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The study included 46 patients with suspected WAS from 2 months to 17 years old. Patients were examined from January 2018 to January 2020. WAS gene defect was confirmed in 35 patients. It was calculated that normal threshold value for WASP expression is 7.07 with sensitivity and specificity 100% and 93.1% respectively. Besides negative correlation between WASP expression index and WAS clinical severity was shown (r = –0.63). This flow cytometry assay can be used for chimerism detection in WAS patients after HSCT. The flow cytometry assay for WASP protein evaluation is rapid, highly sensitive and highly specific. It allows to speed up diagnosis of this disorder.
30 June 2025 in Pediatric Hematology/Oncology and Immunopathology
ЗЮЗавидный Тимофей Юрьевич
+14
For NK lymphocyte-enriched biomedical cell product is a pressing issue in clinical biotechnology. Based on numerous scientific and clinical studies, we have settled on the NK lymphocyte expansion protocol with a modified feeder line K562 and peripheralblood mononuclear cells as a starting fraction, not including CD3+ lymphocyte depletion step. In this paper, we present the results of a validation process of NK lymphocyte-enriched biomedical cell product manufacturing. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The resulting cell productsmet all stated quality control criteria, contained a high percentage of NK cells, and demonstrated strong cytotoxic activity against the THP-1 and Jeko-I cell lines. Expansion folds allowed us to achieve the desired clinical dosage in all processes. Thesurface marker expression profile of the expanded NK cells corresponded to an activated and highly proliferative phenotype. The residual lymphocytes were represented mainly by T cells with an effector phenotype, and a significant decrease in TCRab percentage was observed compared to the initial fraction. These data provide the basis for a clinical study of the feasibility and safety of the infusions of the cellular products produced according to this protocol for pediatric refractory leukemia treatment.
8 July 2024 in Pediatric Hematology/Oncology and Immunopathology
Today, the use of anti-CD19 biomedical cell products (BMCPs) for the treatment of B-cell malignancies yields impressive results and is becoming ever more popular. Several bioreactors have been developed that allow the manufacturing of high-quality cell products for clinical use. Choosing an appropriate bioreactor is an important step in this process. The aim of this study was to characterize and compare immunophenotypic and functional properties of anti-CD19 BMCPs manufactured using the automated CliniMACS Prodigy system (Miltenyi Biotec, Germany) and the manual G-Rex 10M-CS platform (Wilson Wolf, USA). The manufacturing of BMCPs and subsequent CAR T-cell therapy were carried out at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia. We used T cells from patients who had undergone HSCT as well as from autologous and allogeneic donors. In this study, we employed 26 anti-CD19 BMCPs manufactured using the automated CliniMACS Prodigy system in accordance with the GMP requirements as well as 25 cell products produced with the G-Rex platform. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Quality control was ensured throughout the entire manufacturing cycle and included assessment of cell composition and survival, transduction efficiency, cell expansion, expression of exhaustion markers, and CD19-specific antitumor activity. Our research showed that both manufacturing platforms generate stable high-quality products with sufficient cell expansion, viability and T cell transduction for subsequent CAR-T therapy. However, the median transduction efficiency of the BMCPs produced using the CliniMACS Prodigy platform was statistically significantly higher than that of the BMCPs manufactured using the G-Rex bioreactor (41% vs 26%). The study showed that in the anti-CD19 BMCPs, there was a predominance of Tcm subpopulation over Tem subpopulation, a low expression of exhaustion markers and a pronounced CD19-specific activity. Nevertheless, the percentage of Tcm cells in the BMCPs manufactured using the CliniMACS Prodigy platform was statistically significantly higher than in the BMCPs produced using the G-Rex bioreactor (86.7% CD8+ Tcm cells and 82.3% CD4+ Tcm cells for CliniMACS Prodigy vs 69.0% CD8+ Tcm cells and 72.0% CD4+ Tcm cells for G-Rex). Despite the lower number of anti-CD19 CAR-T cells in the final cell products obtained with the G-Rex bioreactor, in all processes this amount was sufficient for subsequent CAR-T therapy. Thus, the CliniMACS Prodigy and G-Rex platforms can be used to produce high-quality anti-CD19 BMCPs.
8 July 2024 in Pediatric Hematology/Oncology and Immunopathology
Graft-versus-host disease (GVHD) remains the main life-threatening immunologic complication of hematopoietic stem cell transplantation. Despite modern pharmacological approaches for preventing and treating GVHD, there remains a need for new approaches to cure GVHD. Currently, more and more clinical experience is emerging globally in the field of using regulatory T-cell (Treg) therapies for the treatment of refractory GVHD. Manufacturing cell products for Treg therapies has a wide range of protocol variations. We have developed an approach of Treg manufacturing for cell therapy and present data from our experience in manufacturing a haploidentical Treg cell product by combining CD25+ immunomagnetic selection with closed system flowbased cell sorting methods. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study describes the processes of producing 9 Treg cell products. According to the manufacturing protocol described here, it is possible to obtain a cell product that meets the quality control requirements necessary for approval for clinical use. Quality control includes the assessment of the cell composition, viability, and microbiological safety of the product, and is performed at all major stages of production. The final cell product is characterized by consistently high levels of FoxP3-expressing Treg (median: 98%), with a median cell viability of 99.1%, and has a high potential for functional efficacy. Thus, the protocol for producing Treg cell products by combining CD25+ immunomagnetic selection with flow cytometry-based cell sorting methods can be used for the clinical treatment of GVHD.
11 May 2026 in Cytometry Part B: Clinical Cytometry